Page 167 - Development Programs News Today

StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research note issued to investors on Friday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Acorda Therapeutics Price Performance ACOR stock opened at $0.47 on Friday. The company has a quick ratio of 1.83, a current ratio […]

Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) and Acorda Therapeutics (NASDAQ:ACOR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings […]

– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of...

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont...

Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Rating) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 256,700 shares, a drop of 7.4% from the February 28th total of 277,100 shares. Based on an average daily volume of 217,300 shares, the short-interest ratio is […]

Acorda Therapeutics (NASDAQ:ACOR – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Risk & Volatility Acorda Therapeutics has a beta of […]

Acorda Therapeutics (NASDAQ:ACOR – Get Rating) and Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Profitability This table compares Acorda Therapeutics and Adaptimmune Therapeutics’ […]

/PRNewswire/ -- Exos, the industry-leading coaching company that gets people ready for the moments that matter most, today released the Exos Readiness Culture...

Looking to launch your career in tech after college? Check out these internships and early career programs.